Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
36.90
+0.29 (0.79%)
At close: Jun 5, 2025, 4:00 PM
36.91
+0.01 (0.03%)
After-hours: Jun 5, 2025, 4:00 PM EDT
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $139.29M in the quarter ending March 31, 2025, with 27.99% growth. This brings the company's revenue in the last twelve months to $590.69M, up 33.46% year-over-year. In the year 2024, Ultragenyx Pharmaceutical had annual revenue of $560.23M with 29.01% growth.
Revenue (ttm)
$590.69M
Revenue Growth
+33.46%
P/S Ratio
5.80
Revenue / Employee
$456,483
Employees
1,294
Market Cap
3.48B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 560.23M | 125.98M | 29.01% |
Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RARE News
- 2 days ago - Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 22 days ago - Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewsWire
- 4 weeks ago - Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 5 weeks ago - Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 6 weeks ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline - Seeking Alpha